Literature DB >> 20547651

Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis.

Catherine A Panozzo1, Lauren J Stockman, Aaron T Curns, Larry J Anderson.   

Abstract

OBJECTIVE: For children in the United States who are at high risk for severe respiratory syncytial virus (RSV) infection, the American Academy of Pediatrics (AAP) recommends administering immunoprophylaxis during the RSV season. We present an approach to using surveillance data to help guide application of AAP recommendations for immunoprophylaxis to local patterns of RSV outbreaks.
METHODS: We analyzed data from laboratories that report consistently to the National Respiratory and Enteric Virus Surveillance System from 1992 to 2007. Local RSV seasons were defined and an immunoprophylaxis schedule was determined by using the median onset dates from each laboratory during 2002-2007. We applied these dates to 10 preceding years of RSV detection data. We compared how well the 5-year median-based method and a fixed date method were able to match the timing of immunoprophylaxis to the RSV season.
RESULTS: Nineteen laboratories met our inclusion criteria and generally experienced only 1 RSV outbreak per season. Five years of data gave similar median onset/offset dates and season duration, as did 10 years and 15 years of data. The 5-year median schedule increased the number of seasons that children were protected at the season onset by 15% compared with a fixed start date of November 1 and identified communities that experienced RSV seasons with extended durations.
CONCLUSIONS: The 5-year median method can be used to characterize timing of RSV seasons and optimally apply the current AAP recommendations for timing of palivizumab prophylaxis to the local community.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20547651     DOI: 10.1542/peds.2009-3221

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  14 in total

1.  Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.

Authors:  Daniel M Weinberger; Joshua L Warren; Claudia A Steiner; Vivek Charu; Cécile Viboud; Virginia E Pitzer
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

2.  Respiratory syncytial virus-associated hospitalizations in pre-mature infants in Lima, Peru.

Authors:  Theresa J Ochoa; Rossana Bautista; Carmen Dávila; José Antonio Salazar; Carlos Bazán; Oscar Guerra; Jean Pierre Llanos; Luis López; Alonso Zea-Vera; Lucie Ecker
Journal:  Am J Trop Med Hyg       Date:  2014-10-06       Impact factor: 2.345

3.  Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.

Authors:  Alexander Gutfraind; Alison P Galvani; Lauren Ancel Meyers
Journal:  JAMA Pediatr       Date:  2015-04       Impact factor: 16.193

4.  Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review.

Authors:  Kimberly Bloom-Feshbach; Wladimir J Alonso; Vivek Charu; James Tamerius; Lone Simonsen; Mark A Miller; Cécile Viboud
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

5.  Trends in rotavirus from 2001 to 2015 in two paediatric hospitals in Atlanta, Georgia.

Authors:  B K Sederdahl; J Yi; R C Jerris; S E Gillespie; L F Westblade; C S Kraft; A L Shane; E J Anderson
Journal:  Epidemiol Infect       Date:  2018-02-12       Impact factor: 4.434

6.  Respiratory syncytial virus surveillance in the United States, 2007-2012: results from a national surveillance system.

Authors:  Catherine Balderston McGuiness; Marnie L Boron; Brett Saunders; Laurel Edelman; Veena R Kumar; Karma M Rabon-Stith
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

7.  Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States.

Authors:  Virginia E Pitzer; Cécile Viboud; Wladimir J Alonso; Tanya Wilcox; C Jessica Metcalf; Claudia A Steiner; Amber K Haynes; Bryan T Grenfell
Journal:  PLoS Pathog       Date:  2015-01-08       Impact factor: 6.823

8.  Challenges to evaluating respiratory syncytial virus mortality in Bangladesh, 2004-2008.

Authors:  Lauren J Stockman; W Abdullah Brooks; Peter K Streatfield; Mustafizur Rahman; Doli Goswami; Kamrun Nahar; Mohammed Z Rahman; Stephen P Luby; Larry J Anderson
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

9.  Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations.

Authors:  André Ricardo Ribas Freitas; Maria Rita Donalisio
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-03-29       Impact factor: 2.743

10.  The impact of influenza and respiratory syncytial virus on hospitalizations for lower respiratory tract infections in young children: Slovenia, 2006-2011.

Authors:  Veronika Učakar; Maja Sočan; Katarina Prosenc Trilar
Journal:  Influenza Other Respir Viruses       Date:  2013-06-20       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.